METHOD OF MEASURING A BIOLOGICAL LIGAND

Abstract: A method of determining a biological ligand which is highly sensitive and specific and which is suitable for use as a clinical test for the determination of physiological subst­ ances and trace components in humoral fluid comprises allowing there to coexist in an aqueous medium a system comprising (A) a ligand (1) to be measured, (B) either a combination (1) of an antibody against the ligand (1) and an enzyme capable of acting on a water-insoluble macromole­ cular substance or a combination (2) of a said enzyme and a ligand (2) having an antigenic determinant which is an antigenic determinant of said ligand (1), which combination (2) is present in the aqueous medium together with a said antibody, and (C) a said macromolecular substance, deter­ mining the residual activity of the enzyme after it has acted on said macromolecular substance and utilising the mea­ surement thereby obtained as a measure of the biological ligand. The inventive method makes use of the steric hindrance of the combination (1) or (2) for the enzyme reaction which is carried out at the boundary between solid phase and liquid phase.

Description: This invention relates to a method of measuring a biological ligand. The ability to measure the concentration in the blood of a drug administered to a patient is an important factor in the treatment of the patient. Moreover, the detection in the blood of trace components derived from various diseases is important in early diagnosis of the diseases in patients. As these medicinal substances and trace components derived from various diseases can be bound to biological ligands, it is important to be able to measure such biological ligands which incorporate medicinal substances and trace substances derived from various diseases. A humoral fluid such as blood contains various components, and some of them are similar to each other in their molecular weights and/or physiological properties. For this reason, the measurement of such components requires high specificity and high sensitivity. Furthermore, in order to utilise conventional inspection techniques for diagnosis of a disease, the measuring procedure is of necessity to be simple. Various methods of detecting these trace components in blood have been developed, among which enzyme immunoassay is widely employed because of its superior sensitivity and specificity and its ability to allow rapid treatment of a large number of samples. However, the sensitivity of conventional enzyme immunoassay techniques is not sufficient and it is not easy to obtain an exact measurement of concentration because of the complicated washing procedures that are used and the transferring of tubes. The present inventors have investigated various enzyme immunoassay methods using various combinations of a ligand or an antibody and an enzyme or a material having an enzyme inhibitory activity as follows: There is described in Japanese published patent application No.142466/1984 a method of measuring a biological ligand which comprises, contacting a ligand (1) to be measured and a covalently coupled combination of a ligand (2) having an antigenic determinant common to one of the antigenic determinant(s) of the above ligand (1) and biotin or a derivative thereof capable of reacting with avidin or streptoavidin as biotinyl enzyme inhibitor, with an antibody capable of reacting with the above common antigenic determinant in an aqueous solution, contacting the above covalently coupled combination with a biotinyl enzyme inhibitor such as avidin, streptoavidin or one of their derivatives capable of reacting with biotin, and measuring the residual biotinyl enzyme activity. In the method of EP-A-0119767 for measuring a biological ligand, there are brought into contact with each other in aqueous solution (a) a ligand to be measured, (b) an enzyme or a covalently coupled combination of an enzyme and a macromolecular substance, and (c) either a covalently coupled combination of an antibody against the above ligand and an antibody against the above enzyme, or a covalently coupled combination of an antibody against the above ligand, an antibody against the above enzyme and a macromolecular substance, determining the residual activity of the enzyme and utilising the result obtained as a measure of the ligand. In our EP-A-0124366, there is disclosed a method of measuring a biological ligand, characterised by bringing into contact with each other in aqueous solution: (A) a biologically active composition comprising firstly an immobilized antibody phase whose antibody is capable of reacting with a ligand (1) to be measured or an immobilised phase of a biological ligand (2) which is capable of reacting with said antibody and secondly an immobilised biotinyl enzyme phase or immobilized biotinyl enzyme inhibitor phase, (B) a water-soluble material covalently coupled combination of whichever of said ligand (2) or said antibody on the one hand and a biotinyl enzyme inhibitor or a biotinyl enzyme on the other hand are absent from the biologically active composition, the biotinyl enzyme inhibitor then being one which is capable of reacting with the biotinyl enzyme of the biologically active composition or the biotinyl enzyme then being one which is capable of reacting with the biotinyl enzyme inhibitor of the biologically active composition, and (C) the ligand (1) to be measured, and measuring the residual biotinyl enzyme activity or the residual biotinyl enzyme inhibitory activity of said biologically active composition or said aqueous solution and utilizing the result as a measure of the ligand. Finally in our EP-A- 0132292 (European Patent Application No.84304093.2), there is described a method of measuring a biological ligand which comprises bringing into contact with each other in aqueous solution (A) a ligand (1) to be measured and, (B) a covalently coupled combination of a biotinyl enzyme inhibitor and a ligand (2) having an antigenic determinant which is also an antigenic determinant of ligand (1) and (C) an antibody capable of reacting with the said antigenic determinant, adding a biotinyl enzyme, measuring the residual biotinyl enzyme activity and utilising the measurement thereby obtained as a measure of the biological ligand. It is an object of this invention to provide a yet further method of measuring a biological ligand, which possesses high sensitivity and simplicity of operation. This invention is based on the discovery that when a covalently-coupled combination of an enzyme capable of acting on a water-insoluble macromolecular substance and a ligand or an antibody is employed as the covalently coupled combination of substances and brought into contact with the ligand to be measured, the ligand in a test sample can be detected to a high degree of sensitivity and the operation is relatively simple to carry out. According to the present invention, there is thus provided a method of measuring a biological ligand which comprises, bringing into contact with each other in aqueous solution (A) a ligand (1) to be measured and (B) either a covalently coupled combination (1) of an antibody against the ligand (1) and an enzyme capable of acting on a water-insoluble macromolecular substrate or a covalently coupled combination (2) of a said enzyme and a ligand (2) having an antigenic determinant which is an antigenic determinant of said ligand (1), which covalently coupled combination (2) is present in the aqueous medium together with a said antibody, said antibody reacting (c) with said ligand (1) or (b) with said ligand (1) and with said ligand (2) to which said enzyme is covalently coupled digesting with said enzyme (C) a said water insoluble macromolecular substrate, determining the residual activity of the enzyme after it has acted on said macromolecular substrate and utilising the measurement thereby obtained as a measure of the biological ligand. The subject to be measured by the method of the invention is termed herein ligand (1). The ligand (1) will be a substance having one or more antigenic determinants, and includes, for example, hormones derived from various endocrine glands, plasma proteins such as immunoglobulin, albumin and ferritin, viral antigens such as HB antigen, bacteria, α-fetoprotein, and carcinoembryonic antigens. This ligand (1) may also be a hapten or may be a first antibody in the double antibody method. The ligand (1) may furthermore be the conjugate of the antigen to be measured and a first antibody as in the double antibody method. The fluid medium acting as the source of ligand (1) may be inter alia , serum or urine. The ligand (2) which is optionally used will also have one or more antigenic determinants and at least one antigenic determinant must be an antigenic determinant of the ligand (1). All the antigenic determinants of ligand (2) may be antigenic determinants of ligand (1), and accordingly, ligand (2) may be identical with the ligand (1). The antibody which is used should be the antibody against this common antigenic determinant when two ligands are present in the aqueous medium being used. The antibody whether or not a ligand (2) is used may include fragments of immunoglobulin such as F(ab')₂, Fab' and Fab. Such an antibody may be produced by following any suitable method for producing an antibody. For example, the ligand (1), the ligand (2) or a covalently coupled combination of either of these ligands and a protein material is injected once or several times into the subcutaneous region of the back, foot pad or femoral muscle of a warm-blooded animal such as a rabbit, goat, horse, guinea pig or chicken, in an amount of from 0.3 to 2 mg per kg together with an adjuvant to produce the antibody in a humoral fluid such as serum. This humoral fluid may be used as it is as the antibody, although, the antibody is preferably separated by following a conventional immunoglobulin isolation method. Alternatively, the antibody may be produced as a monoclonal antibody. In this case, one of the above antigens is injected several times into the abdominal cavity of a mouse together with an adjuvant, and the spleen of the mouse is excised. The spleen cell is fused with a mouse myeloma cell by a conventional method involving the use of polyethylene glycol. The hybridoma thus obtained is cultured and cloned, and the cell which is capable of producing the desired antibody is obtained. This cell is injected into the abdominal cavity of a mouse, and multiplied. Then, ascites are collected, and the desired antibody is separated from the ascites. Should the antibody not be covalently coupled combined with the enzyme, as will be described hereinafter and should the enzyme activity not vary appreciably through the reaction of the antibody with the ligand (2) portion of the covalently coupled combination which is also described hereinafter, a macromolecular compound may preferably be bound to the antibody prior to use. Preferred macromolecular compounds for this purpose are water-soluble, and their molecular weights are greater than 100,000 daltons. Examples of such macromolecular compounds include polysaccharides and their derivatives such as soluble dextran, carboxymethyl dextran, dextran with induced amino group and amylose, proteins such as gelatin, hemocyanin and ferritin, and polyethylene glycol The macromolecular compound may be covalently coupled to the antibody by one of the coupling methods described hereinafter. The enzyme is able to act on a water-insoluble macromolecular substrate (C). Enzymes whose activities are easily measured are preferably used. Examples of such enzymes include α-amylase, cellulase, collagenase, mannase, protease, elastase and lipase. The enzyme is initially covalently coupled with the antibody or the ligand (2). When it is covalently coupled with the antibody, ligand (2) is not used. On the other hand, when it is covalently coupled with ligand (2), the antibody may be used in its natural form or covalently coupled with a macromolecular compound. The method of covalently coupling the enzyme and the antibody or the ligand (2) may be selected in accordance with the functional groups of substances to be combined. Such functional groups include, amino groups, carboxyl groups, hydroxyl groups, thiol groups, imidazole groups and phenyl groups. The coupling of amino groups may be carried out by many methods such as the diisocyanate method, the glutaraldehyde method, the difluorobenzene method, and the benzoquinone method. When coupling an amino group and a carboxyl group, it is possible to use the peptide-binding method using a carboxyl group coupled to a succinimido ester and the carbodiimide method or to use Woodward reagent. The periodate oxidation method (Nakane method) where a bridge is formed between amino groups and sugar chains may also be utilised. When using a thiol group for the aforesaid binding, a carboxyl group may be first converted to a succinimido ester group, and this ester group is then allowed to react with cysteine to introduce the thiol group thereof. The two thiol groups are then linked by using a thiol-reactive bifunctional cross-linking reagent such as phenylene- bismaleimide. Typical of methods utilising a phenyl group are the diazotization method and the alkylation method. In addition to the foregoing methods, it is possible to use a suitable method selected from the various methods described in "Methods in Immunology and Immunochemistry" (C.A. Williams et al., 1976, Academic Press N.Y.). and "Koso Meneki Sokutei-ho" (E. Ishikawa et al., 1978, Igaku-shoin (Japan)). The molar ratio of components used in forming the covalently coupled combination is not limited to 1:1, and other suitable ratios can be easily selected. After the coupling reaction, the covalently coupled combination produced is purified by gel filtration, ion-exchange chromatography and affinity chromatography,and lyophilized, if desired. When the enzyme is covalently coupled with the antibody, the antibody thus combined is then brought into contact with the ligand (1) to be measured. When the enzyme is covalently coupled with the ligand (2), the antibody is first brought into contact with the ligand (1) and the ligand (2) in its covalently coupled combination with the enzyme. In the latter case, the order of contacting is not limited, and either the ligand (1) or the covalently coupled combination of enzyme and ligand (2) may first be allowed to contact the antibody. Of course, both ligand (1) and the covalently coupled combination of enzyme and ligand (2) may be allowed to contact the antibody at the same time. The temperature of the aqueous solution is usually kept at from 20 to 45 o C, and the pH is usually kept at from 4 to 8.5. In order to keep the pH constant, a buffer solution such as a phosphate buffer solution or an acetate buffer solution may be employed. Since the amounts of the covalently coupled combination of enzyme and ligand (2) or the covalently coupled combination of enzyme and antibody, as the case may be, the antibody, when used on its own, will vary, inter alia , according to their character, the character of ligand (1) and the contacting conditions, the amounts are preferably determined by a preliminary test. If the antibody is not covalently coupled with the enzyme and if the enzyme activity has been found not to vary appreciably through the reaction of the antibody with the ligand (2) portion of the covalently coupled combination of enzyme and ligand (2), a second antibody may be reacted with the antibody covalently coupled to the ligand (2) portion. The second antibody may be prepared by following the method previously described herein. Subsequently, the ligand (1), the covalently coupled combination of substances and, when appropriate, antibody are brought into contact in an aqueous medium with a water-insoluble macromolecular (C). The covalently coupled combination may initially be in the reaction solution to which the water-insoluble macromolecular substance is added or it may also be separate from the reaction solution, too. The macromolecular (C) is then subjected to the action of the enzyme, and it is usually a conventional substrate for the enzyme. The macromolecular substance is characterised by its being insoluble in water. Hence the interacting of the macromolecular substance and the enzyme portion of the covalently coupled combination thereof with ligand(s) and antibody is carried out at the boundary between solid and solution, and as a result, steric hindrance of macromolecule(s) bound to the enzyme is a major factor. This steric hindrance is supported by an experiment which has been carried out wherein a pentose and an insoluble starch were digested by an α-amylase which was in its natural form or which had previously been allowed to combine with a macromolecule. The results of the experiment showed that the enzyme activity was scarcely lowered by the covalent coupling of the enzyme with the macromolecule when the substrate was pentose, while it was considerably lowered when the substrate was the insoluble starch. Macromolecular substance/enzyme pairings which can be used include insoluble starches in the case of α -amylase, celluloses in the case of cellulase, collagen in the case of collagenase, mannan in the case of mannase, insoluble proteins in the case of proteases, elastin in the case of elastase, and various lipids in the case of lipases. When a macromolecular substance is normally water-soluble, it may also be used in the method of this invention if it has been subjected to insolubilisation. The insolubilisation may be carried out by covalent coupling with an insoluble carrier material or by subjecting the macromolecular substance to homopolymerization. The conditions under which the enzyme reaction will be carried out will depend on the enzyme being employed. After the reaction, the residual magnitude of the activity of the enzyme prior to its acting on the macromolecular substance will be determined by detecting changes in the reaction mixture, such as the concentration of a decomposition product or the decrease in the substrate for the enzyme. The method of this invention enables a biological ligand to be detected and determined in high sensitivity and in high specificity. The operation of this method is simple, and a biological ligand can easily and inexpensively be determined. There are essentially no restrictions on the ligand to be measured, although the present method is especially suitable for use when measuring ligands having relatively high molecular weights. When using a covalently coupled combination of the antibody and enzyme, since the ligand is used only as the antigen which is necessary to produce the antibody, the amount of the ligand present may be very small. Accordingly, this method is effective when only a small amount of the ligand can be obtained and when the ligand is extremely expensive. The following Examples illustrate this invention: EXAMPLE 1 i) Preparation of Cellulose Substrate A piece of filter paper 20 cm x 20 cm was cut. The piece was immersed in a reactive blue solution prepared by dissolving 5 g of reactive blue and 5 g of Na₂CO₃ in 200 ml of distilled water, and kept at 60 o C for 3 days with occasional stirring. The filter paper was then sufficiently washed with distilled water to remove the excess dye. Subsequently, the filter paper was dried in a dryer having a thermostat, and cut into pieces sized 1 cm x 5 cm which were to be the substrate for cellulase. ii) Preparation of Covalently Coupled Combination of Cellulose and Human Human IgG 10 mg of cellulase were dissolved in 2 ml of 0.1 M phosphate buffer solution of pH 6.0, and 200 µl of a 2 mg/ml 4-maleimidomethyl cyclohexane-1-carboxylic acid succinimido ester (CHMS) dimethyl sulphoxide solution were added. The mixture was allowed to stand at ambient temperature for one hour. Gel filtration using Sephadex G-25 (Sephadex is a Registered Trade Mark) was carried out and unreacted CHMS was removed from the reaction mixture. The reaction mixture was then concentrated to 1 ml to obtain CHM-induced cellulase. Separately, 10 mg of human IgG were dissolved in 2 ml of 0.1 M phosphate buffer solution of pH 7.5. 200 µl of a 9 mg/ml S-acetylmercaptosuccinic anhydride (SAMS) dioxane solution were added to this, and allowed to stand at 37 o C for 1 hour. Subsequently, 200 µl of 1 M hydroxylamine aqueous solution of pH 7.5 were added, and the reaction mixture obtained was allowed to stand at 37 o C for 30 minutes. Gel filtration using Sephadex G-25 was carried out, and unreacted SAMS was removed from the reaction mixture. HS-human IgG solution thus obtained was added to 1 ml of the above CHM-induced cellulase, and allowed to stand at 37 o C for 2 hours. The reaction mixture was subjected to gel filtration using Sephacryl S-300 (Sephacryl is a Registered Trade Mark) and in this way the target combination of cellulase and human IgG was obtained. iii) Measurement of Human IgG 50 µl of a standard solution containing human IgG were added to 50 µl of a solution containing the above covalently coupled combination of enzyme (cellulase) and ligand (human IgG). 5 l of anti-human IgG goat serum were added to this mixture, and allowed to stand at 37 o C for 1 hour. 1 ml of 0.1 M acetate buffer solution pH 5.0 was added to this, and one piece of the blue cellulose filter paper prepared in step i) was then added. After 1 hour, the absorbance at 620 nm of the reaction solution was measured. The relationship between the human IgG concentrations in standard solutions of different concentration and the absorbance is shown in the following Table 1. Human IgG (µg) A₆₂₀ nm 0 0.280 100 0.380 200 0.490 400 0.630 800 0.990 2000 1.220 These results were suitable for plotting as a standard curve to enable the human IgG concentration of solutions of unknown concentration to be determined. EXAMPLE 2 i) Preparation of CHM-induced Amylase 5 mg of Bacillus subtilis amylase were dissolved in 1 ml of 0.1 M phosphate buffer solution of pH 6.3. 100 µl of 2 mg/ml CHMS dimethylformamide (DMF) solution were added and the reaction mixture was allowed to stand at ambient temperature for 1 hour. The reaction mixture was then introduced into a Sephadex G-25 column, and gel filtration was carried out by using 0.1 M phosphate buffer solution of pH 6.3. The void fractions were collected to obtain the target CHM-induced amylase. ii) Preparation of SH-induced α-Fetoprotein 5 mg of α-fetoprotein were dissolved in 0.1 M phosphate buffer solution containing 5 mM EDTA. 100 µl of 9 mg/ml SAMS DMF solution was added to this, and allowed to react at 37 o C for 1 hour. 110 µl of 1M aqueous hydroxylamine solution of pH 7.5 were added to the reaction mixture which was allowed to warm up at 37 o C for 30 minutes. Subsequently, gel filtration of the reaction mixture using Sephadex G-25 was carried out and the void fractions were collected to obtain the target SH-induced α-fetoprotein. iii) Preparation of Covalently Coupled Combination of Amylase and α-Fetoprotein The CHM-induced amylase solution produced in step i) was mixed with the SH-induced α-fetoprotein solution from step ii). The mixture was concentrated to 1 ml, and allowed to react at 4 o C overnight. The reaction solution was introduced into a Sephacryl SD-300 column, and gel filtration was carried out by using 20 mM phosphate buffered saline solution of pH 7.0. The fractions containing the covalently coupled combination of enzyme and ligand in a molar ratio of 1:1 were collected. iv) Measurement of α-Fetoprotein 50 µl samples of α-fetoprotein solutions whose concentrations were in the range of 0-2000 ng were each mixed with 50 µl of the covalently coupled combination solution prepared in step iii). 50 µl of 8 µg/ml anti-α-fetoprotein goat IgG solution were added to each mixture, and allowed to react for 20 minutes. 1.0 ml of a suspension of blue starch (made by Pharmacia, Diagnostics, A.B.) was added to each reaction mixture, and allowed to react at 37 o C for 20 minutes. The enzyme reaction was terminated by adding 1 ml of 0.5 N NaOH. The mixture was stirred, and then centrifuged at 3,500 rpm for 2 minutes. The absorbance at 620 nm of the supernatant was measured. The relationship between the α-fetoprotein concentration and the absorbance thus obtained is shown in Figure 1 of the accompanying drawings which provides a standard curve for determining unknown α-fetoprotein concentrations in body fluids. EXAMPLE 3 5 mg of α-amylase were dissolved in 1 ml of 0.1 M carbonate buffer solution of pH 8.0. 100µl of 20 µg/ml 3-carboxytheophylline succinimido ester DMF solution were added to this, and allowed to react at ambient temperature for 1 hour. Gel filtration using a Sephadex G-25 column which had previously been equilibrated with 20 mM phosphate buffered saline solution of pH 6.5 containing 20 mM calcium chloride was carried out, and the void fractions were collected. The fractions were concentrated to 1 ml to obtain an enzyme/ligand covalently coupled combination of theophylline and α-amylase. 50 µl of 800 mg/ml of this covalently coupled combination solution were added to 50 µl of serum, and in order to inhibit human serum amylase, 50 µl of 500 µg/ml anti-human amylase goat IgG were added to the mixture. 50 µl of 15 µg/ml anti-theophylline mouse IgG was also then added, and allowed to react at 37 o C for 30 minutes. 100 µl of this reaction solution were dropped onto a laminate film which consisted of a polystyrene film 1, a cation-exchange resin layer 2, a reflection layer 3 and a blue starch layer 4 as shown in Figure 2 of the accompanying drawings. The amylase activity at ambient temperature after 20 minutes was measured by using a reflectometer. This procedure was repeated, but with the inclusion of theophylline in different concentrations in the reaction solution so that residual amylase activity decreased as theophylline concentration increased. The relationship between the theophylline concentration and the reflection intensity thus obtained as a measure of enzyme activity is shown in Figure 3 of the accompanying drawings which is thus a standard curve for use to determine the theophylline concentration in a test specimen of serum of unknown theophylline concentration. EXAMPLE 4 i) Preparation of Cellulase Substrate Blue cellulose filter paper samples sized 1 cm x 5 cm were prepared in the same manner as described in step i) of Example 1. ii) Preparation of Covalently Coupled combination cellulase and Anti-Human IgG Goat IgG CHMS-induced cellulase 1 ml was prepared in the same manner as described in the first part of step ii) of Example 1. Separately, 10 mg of anti-human IgG goat IgG were dissolved in 2 ml of 0.1 M phosphate buffer solution containing 5 mM EDTA. 200 µl of 9 mg/ml SAMS dioxane solution were added to this, and allowed to stand at 37 o C for 1 hour. 200 µl of 1 M hydroxylamine aqueous solution of pH 7.5 were added, and the reaction mixture was allowed to stand at 37 o C for 30 minutes. The reaction mixture was then subjected to gel filtration using Sephadex G-25, and unreacted SAMS was removed. This HS-anti-human IgG goat IgG solution was added to 1 ml of the aforesaid CHM-induced cellulase, and allowed to stand at 37 o C for 2 hours. The reaction mixture was separated by gel filtration using Sephacryl SD-300, and the target enzyme/antibody covalently coupled combination of cellulase and anti-human IgG goat IgG was obtained. iii) Measurement of Human IgG 50 µl of a standard solution containing human IgG were added to 50 µl of a solution containing the above covalently coupled combination of cellulase and anti-human IgG goat IgG, and allowed to stand at 37 o C for 30 minutes. 1 ml of 0.1 M acetate buffer solution pH 5.0 was added, and one piece of the blue cellulose filter paper prepared in step i) was then added. After 1 hour, the absorbance at 620 nm of the reaction solution was measured. The relationship between the human IgG concentration and the absorbance for standard solutions of different human IgG concentration is shown in Figure 4 of the accompanying drawings which is thus a standard curve for enabling unknown human IgG concentrations in fluids to be determined. EXAMPLE 5 i) Preparation of CHM-induced Amylase CHM-induced amylase was prepared from Bacillus subtilis amylase in the manner as described in step i) of Example 2. ii) Preparation of Anti-Human α-Fetoprotein Goat IgG F(ab')₂ 10 mg of anti-human α-fetoprotein goat IgG were dissolved in 2 ml of 0.1 M acetate buffer solution of pH 4.0. 300 µg of pepsin were added to this, and stirring at 37 o C for 18 hours was effected. The solution was adjusted to pH 6.0 by adding 0.1 N NaOH, and introduced into a Sephacryl S-300 column which had been previously equilibrated with 0.1 M phosphate buffered 1 mM EDTA solution of pH 6.3, and eluted using the above phosphate buffer solution without EDTA. Peak fractions corresponding to a molecular weight of about 100,000 were collected, and concentrated to 1 ml to obtain the target anti-human α-fetoprotein goat IgG F(ab')₂. iii) Preparation of Covalently Coupled Combination of Amylase and Anti-Human α-Fetoprotein Goat IgG Fab' 1 ml of 0.1 M phosphate buffered 1 mM EDTA solution of pH 6.0 containing 6 mg of the above anti-human α-fetoprotein goat IgG F(ab')₂ were mixed with 100 µl of 10mg/ml aqueous 2-mercaptoethylamine hydrochloride solution, and stirred at 37 o C for 90 minutes. Gel filtration using a Sephadex G-25 column which had been previously equilibrated with 0.1 M phosphate buffer solution of pH 6.3 was carried out, and unreacted 2-mercaptoethylamine was removed to obtain HS-Fab'. 2 mg of CHM-induced α-amylase prepared in step i) were added, and reaction was allowed to take place at 37 o C for 90 minutes. Subsequently, this reaction mixture was separated by gel filtration using a Sephacryl S-300 column which was equilibrated with 0.1 M acetate buffered 5 mM calcium chloride solution of pH 6.0, and the fractions corresponding to the molecular weights of greater than 200,000 were collected. The fractions were concentrated to obtain the target covalently coupled combination of enzyme and antibody. iv) Measurement of α-Fetoprotein 50 µl samples of α-fetoprotein solutions whose concentrations were in the range of 0-2000 ng were each mixed with 50 µl of the covalently coupled combination solution prepared in the above step iii), and allowed to react for 20 minutes. 1.0 ml of a suspension of blue starch (made by Pharmacia Diagnostics, A.B.) was added to the reaction mixture, and reaction was allowed to take place at 37 o C for 20 minutes. The enzyme reaction was terminated by adding 1 ml of 0.5 N NaOH. The reaction mixture was then stirred and centrifuged at 3,500 rpm for 2 minutes. The absorbance at 620 nm of the supernatant was measured in each case and enabled the relation between the α-fetoprotein concentration and the absorbance which is shown in Figure 5 of the accompanying drawings to be obtained. This provided a standard curve for allowing the α-fetoprotein concentration of specimen fluids to be determined.

Claims: A method of measuring a biological ligand which comprises, bringing into contact with each other in an aqueous solution (A) a ligand (1) to be measured and (B) either a covalently coupled combination (1) of an antibody against the ligand (1) and an enzyme capable of acting on a water-insoluble macromolecular substrate or a covalently coupled combination (2) of a said enzyme and a ligand (2) having an antigenic determinant which is an antigenic determinant of said ligand (1), which covalently coupled combination (2) is present in the aqueous medium together with a said antibody, said antibody reacting (a) with said ligand (1) or (b) with said ligand (1) and with said ligand (2) to which said enzyme is covalently coupled, digesting with said enzyme (C) a said water insoluble macromolecular substrate, determining the residual activity of the enzyme after it has acted on said macromolecular substrate and utilising the measurement thereby obtained as a measure of the biological ligand. The method of claim 1, wherein a covalently coupled combination of said antibody and said enzyme is brought into contact with said ligand (1) in the aqueous medium and the enzyme of said covalently coupled combination is then brought into contact with said macromolecular substance in the aqueous medium. The method of claim 1, wherein a covalently coupled combination of said enzyme and said ligand (2) is brought into contact with said antibody and said ligand (1) in the aqueous medium and the enzyme of said covalently coupled combination is then brought into contact with said water insoluble macromolecular substrate in the aqueous medium. The method of claim 3, wherein said antibody is covalently coupled with a macromolecular compound. The method of claim 4, wherein the macromolecular substance is water-soluble and has a molecular weight which is greater than 100,000 daltons. The method of claims 1 and 3, wherein said ligand (1) and said ligand (2) is a hormone derived from an endocrine gland, a plasma protein, a viral antigen, a bacterial species, α-fetoprotein, a carcinoembryonic antigen, a hapten, a first antibody in the double antibody method or a conjugate of an antigen and a first antibody in the double antibody method. The method of any one of claims 1 and 3 to 6, wherein said ligand (1) and said ligand (2) are the same substance. The method of any preceding claim, wherein said antibody is a fragment of immunoglobulin. The method of any one of claims 1 to 7, wherein said antibody is a monoclonal antibody. The method of any preceding claim, wherein said enzyme is selected from α-amylase, cellulase, collagenase, mannase, proteases, elastase and lipases. The method of claim 10, wherein said macromolecular substance is insoluble starch when the enzyme is α-amylase, a cellulosic material when the enzyme is cellulase, collagen when the enzyme is collagenase, mannan when the enzyme is mannase, an insoluble protein when the enzyme is a protease, elastin when the enzyme is elastase, and a lipid when the enzyme is a lipase. A method of measuring theophylline (1) in a sample of human serum containing amylase (2) which comprises bringing into contact with each other the serum sample containing the theophylline, anti-theophylline mouse IgG as antibody (3) against the theophylline, a covalently coupled combination of α-amylase and theophylline (4) and anti-human amylase goat IgG as an amylase inhibitor (5) whose inhibiting activity against human serum amylase (2) is stronger than that against said α-amylase, said antibody (3) reacting with the theophylline of said sample and the theophylline to which the α-amylase is covalently coupled and said amylase inhibitor (5) reacting with said amylase (2), digesting starch with the α-amylase and determining the residual activity of said α-amylase and utilizing the measurement thereby obtained as a measure of the theophylline in said human serum sample.

Inventors: ASHIHARA, YOSHIHIRO, KASAHARA, YASUSHI
Applicants: FUJIREBIO KABUSHIKI KAISHA ALSO TRADING AS FUJIREBIO INC.
Application year: 1984
Main classification: G01N33
IPC codes: G01N33